Page last updated: 2024-11-01

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Diabetic Nephropathies

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Diabetic Nephropathies in 1 studies

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.

Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nasrallah, R1
Robertson, SJ1
Hébert, RL1

Other Studies

1 other study available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Diabetic Nephropathies

ArticleYear
Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice.
    American journal of nephrology, 2009, Volume: 30, Issue:4

    Topics: Albuminuria; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Body Weight; Creatinine;

2009